Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
- The oversubscribed private financing round, with primary participation from Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, and Cormorant Asset Management, follows continued positive clinical signal from Neurona's ongoing Phase 1/2 clinical trial
- The round recognizes recent FDA alignment to advance NRTX-1001 into the Phase 3 EPIC (EPIlepsy Cell therapy) trial
- The Phase 3 EPIC trial is designed as a single pivotal trial and is intended to support submission of a Biologics License Application (BLA)
SOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an upsized and oversubscribed $102 million financing. New and existing investors in the financing round include Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, and Spur Capital Partners.
Proceeds from the financing will be used to advance the company's wholly owned pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead investigational candidate, NRTX-1001, for drug-resistant mesial temporal lobe epilepsy (MTLE), which is among the most common types of epilepsy. In an ongoing multicenter, open-label Phase 1/2 trial in adults with drug-resistant MTLE, ...
https://www.benzinga.com/pressreleases/25/04/g44625363/neurona-therapeutics-raises-102-million-to-fuel-nrtx-1001-phase-3-epic-epilepsy-trial-and-advance-
